We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 83 of 309 for:    hepatitis b | Recruiting, Not yet recruiting, Available Studies

Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B (MAGIC-101)

This study is not yet open for participant recruitment.
Verified November 2017 by Cttq
Sponsor:
ClinicalTrials.gov Identifier:
NCT03349008
First Posted: November 21, 2017
Last Update Posted: November 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Cttq
  Purpose
This study evaluates the addition of glycyrrhizin to entecavir in the treatment of patients with chronic hepatitis B in China. Half of participants will receive magnesium isoglycyrrhizinate followed by oral diammonium glycyrrhizinate and entecavir in combination, while the other half will receive a placebo and entecavir.

Condition Intervention Phase
Chronic Hepatitis b Liver Inflammation Drug: Entecavir Drug: Magnesium Isoglycyrrhizinate Drug: Diammonium Glycyrrhizinate Drug: Magnesium Isoglycyrrhizinate Placebo Drug: Diammonium Glycyrrhizinate Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B

Resource links provided by NLM:


Further study details as provided by Cttq:

Primary Outcome Measures:
  • Change of ALT(Alanine aminotransferase) [ Time Frame: baseline and 24 weeks ]
    The ALT levels of plasma are measured at baseline and at 24 weeks. The normal value was 0-40 U/L.


Secondary Outcome Measures:
  • Change of Liver inflammatory [ Time Frame: baseline and 24 weeks ]
    Liver inflammatory of the liver biopsies is performed at baseline and 24 weeks evaluated by Knodell HAI score.

  • Change of Liver Fibrosis [ Time Frame: baseline and 96 weeks ]
    Liver Fibrosis is performed at baseline and 96 weeks evaluated by Fibroscan examination.


Estimated Enrollment: 480
Anticipated Study Start Date: November 25, 2017
Estimated Study Completion Date: May 31, 2020
Estimated Primary Completion Date: December 31, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Control group
Entecavir treatment with placebo, Magnesium Isoglycyrrhizinate placebo followed by Diammonium Glycyrrhizinate placebo
Drug: Entecavir
Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
Other Name: Entecavir Pill
Drug: Magnesium Isoglycyrrhizinate Placebo
Magnesium Isoglycyrrhizinate Injection Placebo
Other Name: Magnesium Isoglycyrrhizinate Injection Placebo
Drug: Diammonium Glycyrrhizinate Placebo
Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
Other Name: Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
Experimental: Experimental group
Entecavir combined with glycyrrhizin, Magnesium Isoglycyrrhizinate Injection followed by Diammonium Glycyrrhizinate
Drug: Entecavir
Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
Other Name: Entecavir Pill
Drug: Magnesium Isoglycyrrhizinate
Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based
Other Name: Magnesium Isoglycyrrhizinate Injection
Drug: Diammonium Glycyrrhizinate
Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
Other Name: Diammonium Glycyrrhizinate Enteric-coated Capsules

Detailed Description:

Chronic hepatitis B(HBV) has a high prevalence (>8%) in China. Entecavir, aguanosine analog, is a potent and selective inhibitor of HBV DNA polymerase.

Glycyrrhizin has been used for more than 30 years in the treatment of liver diseases in Asian countries, who can relieve necro-inflammatory and liver fibrosis or cirrhosis Recent study has shown that inflammation plays the important role in chronic HBV and fibrosis or cirrhosis disease progression, but antiviral therapy only may not reduce inflammation ideally. The addition of glycyrrhizin to entecavir in the treatment may slow disease progression in patients with chronic HBV and advanced fibrosis or cirrhosis.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hepatitis B surface antigen [HBsAg]-positive,
  • Either hepatitis B e antigen (HBeAg)-positive or HBeAgnegative/hepatitis B e antibody (HBeAb)-positive disease were eligible,
  • Serum alanine aminotransferase (ALT) levels 3-10×the upper limit of normal (ULN),serum total bilirubin(TBIL)levels<2×ULN

Exclusion Criteria:

  • Co-infection with hepatitis C virus, hepatitis D virus, or human immunodeficiency virus;
  • Other forms of liver disease;
  • More than 24 weeks of therapy with a nucleoside or nucleotide analog with activity against HBV, and therapy with any anti-HBV drug within 24 weeks prior to randomization;
  • More than 12 weeks of therapy with liver protectants, and therapy with glycyrrhizin;
  • Has decompensated liver function or has a hint of hepatocellular carcinoma (HCC);
  • During the study patients were not allowed to use other medicines.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Cttq
ClinicalTrials.gov Identifier: NCT03349008     History of Changes
Other Study ID Numbers: Cttq-MAGIC-101
First Submitted: May 4, 2017
First Posted: November 21, 2017
Last Update Posted: November 21, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Cttq:
necro-inflammatory
glycyrrhizin
entecavir
hepatic biological parameters
liver fibrosis

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Viral, Human
Inflammation
Liver Diseases
Digestive System Diseases
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Pathologic Processes
Hepadnaviridae Infections
DNA Virus Infections
Entecavir
Glycyrrhizic Acid
Antiviral Agents
Anti-Infective Agents
Anti-Inflammatory Agents